| 11208496 |
Anti-CD19 antibodies with reduced immunogenicity |
Michael Super, Jonathan Davis |
2021-12-28 |
| 10072092 |
Methods of use of anti-CD19 antibodies with reduced immunogenicity |
Michael Super, Jonathan Davis |
2018-09-11 |
| 9029330 |
Methods of treating cancer using interleukin-12p40 variants having improved stability |
Gordon D. Webster, Suzanne P. McKenzie, Kin-Ming Lo |
2015-05-12 |
| 8957195 |
Anti-CD19 antibodies with reduced immunogenicity |
Michael Super, Jonathan Davis |
2015-02-17 |
| 8907066 |
Antibody fusion proteins with a modified FcRn binding site |
Kin-Ming Lo |
2014-12-09 |
| 8691952 |
Anti-CD19 antibodies with reduced immunogenicity |
Michael Super, Jonathan Davis |
2014-04-08 |
| 8188248 |
Nucleic acids encoding interleukin-12P40 variants with improved stability |
Gordon D. Webster, Suzanne P. McKenzie, Kin-Ming Lo |
2012-05-29 |
| 7888071 |
DNA encoding IL-2 fusion proteins with modulated selectivity |
Stephen D. Gillies, Kin-Ming Lo |
2011-02-15 |
| 7872107 |
Interleukin-12p40 variants with improved stability |
Gordon D. Webster, Suzanne P. McKenzie, Kin-Ming Lo |
2011-01-18 |
| 7462350 |
Cancer treatments including administering IL-2 fusion proteins with modulated selectivity |
Stephen D. Gillies, Kin-Ming Lo |
2008-12-09 |
| 7186804 |
IL-2 fusion proteins with modulated selectivity |
Stephen D. Gillies, Kin-Ming Lo |
2007-03-06 |
